PGEN — Precigen, Inc.

Summary of Precigen, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: For Q4 2025, Precigen reported net product revenue of $3.4 million, marking a significant increase from $3.2 million in 2024. Total revenue for the year was $9.7 million, up 149% year-over-year.
• Net Loss: The net loss attributable to common shareholders was $429.6 million, or $1.37 per share, which included noncash items totaling $318.5 million related to preferred stock warrants.
• Cash Position: The company ended the year with $100.4 million in cash and equivalents, expected to fund operations through cash flow breakeven anticipated in 2026.

2. Strategic Updates and Business Highlights

• Product Launch: The company successfully launched Papzimia, the first approved treatment for adult recurrent respiratory papillomatosis (RRP), with commercial sales starting in November 2025.
• Market Adoption: Over 300 patients are now engaged in the Precigen patient support hub, indicating strong demand. The company has expanded payer coverage to approximately 215 million lives, covering nearly 90% of insured lives in the U.S.
• Clinical Data: Papzimia received full FDA approval with a broad label, reflecting its efficacy and potential for redosing, which has been positively received by healthcare providers.
• Future Trials: Plans are underway to initiate a clinical trial for pediatric RRP and to pursue marketing authorization in Europe.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Projection: The company anticipates revenues for Q1 2026 to exceed $18 million, reflecting strong momentum from the Papzimia launch.
• Long-term Strategy: Precigen aims to transition from an R&D-focused entity to a revenue-generating commercial biotech, with ongoing efforts to enhance patient access and payer engagement.

4. Bad News, Challenges, or Points of Concern

• High Net Loss: The substantial net loss reported raises concerns about the company's financial sustainability, although it is attributed to nonrecurring items.
• R&D Expense Management: While R&D expenses decreased by 22.1%, the significant increase in selling, general, and administrative expenses by 69.8% highlights the costs associated with the commercial launch, which may pressure future profitability.
• Market Competition: The company faces potential competition as other therapies may enter the RRP market, although the unique efficacy of Papzimia is expected to provide a competitive edge.

5. Notable Q&A Insights

• Patient Flow and Reimbursement: Management indicated that the conversion of patients from the support hub to receiving treatment is progressing well, aided by the upcoming permanent J-code expected to streamline reimbursement processes.
• Community Engagement: The company is seeing positive uptake in community practices, which could significantly contribute to overall business growth.
• Payer Mix: The current payer mix is approximately 60-65% commercial, with expectations for gross-to-net revenue in the high teens to low twenties.
• European Expansion: The EMA application for Papzimia is under review, with positive feedback from European physicians, although no specific timeline for approval was provided.

Overall, Precigen is experiencing a pivotal transition with the successful launch of Papzimia, but challenges remain regarding financial losses and market competition. The company is optimistic about future growth driven by strong early sales and strategic initiatives.